The MindScape
Parkinson's Protocol

Why Progressive Dosing Matters for Parkinson's

Standard ibogaine treatment for addiction uses a single full-dose HCl session to reset opioid receptors. For Parkinson's disease, the therapeutic target is different: sustained GDNF upregulation to support dopaminergic neuron survival and regeneration. A single dose produces a GDNF spike that dissipates within days. Our protocol is engineered to extend and amplify this window.

The TA booster phase (Days 3 to 9) uses twice-daily doses of ibogaine total alkaloid extract. Each dose contributes to a progressive buildup of noribogaine, the long-acting metabolite primarily responsible for GDNF expression. By the time of the HCl flood session on Day 10, noribogaine levels have been elevated for a full week, creating a sustained neurotrophic environment that a single-session approach cannot achieve.

The post-session microdosing phase (Days 12 to 16) then extends GDNF signaling further, bridging into the at-home microdosing protocol that patients follow for 60 to 90 days post-discharge. The result is weeks of continuous neurotrophic support rather than a single peak event.

Remote Screening and Coordination

Medical records review, neurologist coordination, EKG and bloodwork evaluation, medication management planning, travel logistics.

Arrival, Intake, and Baseline Assessment

Full medical intake. Baseline MDS-UPDRS administration, timed motor assessments (finger tapping, gait speed, sit-to-stand), tremor amplitude measurement, cognitive screening. Medication schedule confirmed. Gentle acclimatization to facility.

TA Booster Phase (Core GDNF Buildup)

Twice-daily ibogaine TA doses, morning and evening. Each session monitored by nursing staff. Daily vitals, cardiac monitoring, and neurological status checks. Concurrent daily physiotherapy, movement therapy, and targeted exercise (which independently amplifies GDNF). Nutritional support optimized for neurological recovery. No full psychedelic experience during this phase; patients remain functional and mobile.

HCl Flood Session

Full-dose ibogaine HCl administered under continuous physician and nursing supervision. 12 to 18 hour monitored experience. Continuous cardiac monitoring (telemetry), IV access, oxygen saturation monitoring. The session initiates peak GDNF upregulation on top of the already-elevated noribogaine baseline from the booster phase. Most patients describe a deeply introspective experience.

Microdosing, Integration, and Recovery

Structured microdosing every 2 to 3 days to sustain GDNF signaling. Daily integration sessions with clinical psychologist. Continued physiotherapy and movement therapy. Neurological monitoring tracks emerging changes in motor function. Yoga, meditation, and sound therapy support overall recovery.

Discharge Assessment and Protocol Handoff

Comprehensive neurological reassessment: repeat MDS-UPDRS, timed motor tests, tremor amplitude. Side-by-side comparison with Day 1 baseline. At-home microdosing protocol finalized. Caregiver briefing on home protocol support. Full documentation prepared for patient's neurologist. 30/60/90-day follow-up schedule confirmed.

GDNF: Why This Protein Matters for Parkinson's

Glial cell line-derived neurotrophic factor (GDNF) is one of the most potent neuroprotective proteins known for dopaminergic neurons. In preclinical models, direct GDNF delivery to the substantia nigra has reversed motor deficits and restored dopaminergic neuron counts. Human clinical trials of surgically infused GDNF have shown clinical benefit, but the delivery method (requiring neurosurgery) has limited widespread adoption.

Ibogaine and its metabolite noribogaine cross the blood-brain barrier naturally and upregulate endogenous GDNF production. This means the brain increases its own GDNF output rather than relying on external delivery. The progressive TA booster approach amplifies this effect by maintaining elevated noribogaine levels over days rather than hours, extending the total neurotrophic exposure.

We are transparent that large-scale clinical trials of ibogaine for Parkinson's have not been conducted. The mechanistic rationale is robust and supported by preclinical evidence, and our clinical observations are consistent with what GDNF-mediated neuroprotection would predict. We contribute all anonymized outcome data to the broader research effort.

Safety Infrastructure Throughout the Protocol

What's Included

14 to 18 day all-inclusive neuroregeneration program. Includes caregiver accommodation. No hidden fees. Contact us to discuss your neurological history and determine whether this protocol is appropriate.

Protocol Questions